Annotation Detail
Information
- Associated Genes
- MET
- Associated Variants
-
MET OVEREXPRESSION
(
ENST00000318493.11 )
MET OVEREXPRESSION ( ENST00000318493.11 ) - Associated Disease
- uveal melanoma
- Source Database
- CIViC Evidence
- Description
- In this study the authors screened for growth factors that elicited resistance in newly characterized metastatic uveal melanoma cell lines to clinical-grade MEK inhibitors, trametinib and selumetinib, showing that neuregulin 1 (NRG1) and hepatocyte growth factor (HGF) provide resistance to MEK inhibition. Trametinib enhances the responsiveness to NRG1 and sustained HGF-mediated activation of AKT. Targeting ERBB3 and cMET could overcome resistance to trametinib.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/3038
- Gene URL
- https://civic.genome.wustl.edu/links/genes/52
- Variant URL
- https://civic.genome.wustl.edu/links/variants/621
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Uveal Melanoma
- Evidence Direction
- Supports
- Drug
- Selumetinib,Trametinib
- Evidence Level
- D
- Clinical Significance
- Resistance
- Pubmed
- 25952648
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Selumetinib | Resitance or Non-Reponse | true |
| Trametinib | Resitance or Non-Reponse | true |